Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse

doi:10.1007/s00125-018-4729-5

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse

Department of Clinical Medicine

540 Citations (Scopus)

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Original language	English
Journal	Diabetologia
Volume	61
Issue number	12
Pages (from-to)	2461-2498
Number of pages	38
ISSN	0012-186X
DOIs	https://doi.org/10.1007/s00125-018-4729-5
Publication status	Published - 1 Dec 2018

Keywords

Cardiovascular Diseases/drug therapy
Consensus
Diabetes Mellitus, Type 2/drug therapy
Europe
Glucagon-Like Peptide-1 Receptor/agonists
Heart Failure/drug therapy
Humans
Hyperglycemia/drug therapy
Hypoglycemic Agents/therapeutic use
Insulin/therapeutic use
Liraglutide/therapeutic use
Renal Insufficiency, Chronic/drug therapy
Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
United States

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-018-4729-5

s00125-018-4729-5.pdfFinal published version, 4.54 MB

Cite this

Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61(12), 2461-2498. https://doi.org/10.1007/s00125-018-4729-5

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). / Davies, Melanie J; D'Alessio, David A; Fradkin, Judith et al.

In: Diabetologia, Vol. 61, No. 12, 01.12.2018, p. 2461-2498.

Research output: Contribution to journal › Journal article › Research › peer-review

Davies, MJ, D'Alessio, DA, Fradkin, J, Kernan, WN, Mathieu, C, Mingrone, G, Rossing, P, Tsapas, A, Wexler, DJ & Buse, JB 2018, 'Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)', Diabetologia, vol. 61, no. 12, pp. 2461-2498. https://doi.org/10.1007/s00125-018-4729-5

@article{34515ed3124c4ea6a4b88ed81cd81af9,

title = "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)",

abstract = "The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.",

keywords = "Cardiovascular Diseases/drug therapy, Consensus, Diabetes Mellitus, Type 2/drug therapy, Europe, Glucagon-Like Peptide-1 Receptor/agonists, Heart Failure/drug therapy, Humans, Hyperglycemia/drug therapy, Hypoglycemic Agents/therapeutic use, Insulin/therapeutic use, Liraglutide/therapeutic use, Renal Insufficiency, Chronic/drug therapy, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, United States",

author = "Davies, {Melanie J} and D'Alessio, {David A} and Judith Fradkin and Kernan, {Walter N} and Chantal Mathieu and Geltrude Mingrone and Peter Rossing and Apostolos Tsapas and Wexler, {Deborah J} and Buse, {John B}",

year = "2018",

month = dec,

day = "1",

doi = "10.1007/s00125-018-4729-5",

language = "English",

volume = "61",

pages = "2461--2498",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

AU - Davies, Melanie J

AU - D'Alessio, David A

AU - Fradkin, Judith

AU - Kernan, Walter N

AU - Mathieu, Chantal

AU - Mingrone, Geltrude

AU - Rossing, Peter

AU - Tsapas, Apostolos

AU - Wexler, Deborah J

AU - Buse, John B

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

AB - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

KW - Cardiovascular Diseases/drug therapy

KW - Consensus

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Europe

KW - Glucagon-Like Peptide-1 Receptor/agonists

KW - Heart Failure/drug therapy

KW - Humans

KW - Hyperglycemia/drug therapy

KW - Hypoglycemic Agents/therapeutic use

KW - Insulin/therapeutic use

KW - Liraglutide/therapeutic use

KW - Renal Insufficiency, Chronic/drug therapy

KW - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

KW - United States

U2 - 10.1007/s00125-018-4729-5

DO - 10.1007/s00125-018-4729-5

M3 - Journal article

C2 - 30288571

SN - 0012-186X

VL - 61

SP - 2461

EP - 2498

JO - Diabetologia

JF - Diabetologia

IS - 12

ER -

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this